We are live on ! Find out more
PACB icon

Pacific Biosciences
PACB

155 hedge funds and large institutions have $809M invested in Pacific Biosciences in 2018 Q4 according to their latest regulatory filings, with 71 funds opening new positions, 45 increasing their positions, 25 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

109% more first-time investments, than exits

New positions opened: 71 | Existing positions closed: 34

89% more call options, than puts

Call options by funds: $8.75M | Put options by funds: $4.62M

80% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 25

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

37% more capital invested

Capital invested by funds: $590M → $809M (+$220M)

31% more funds holding

Funds holding: 118 → 155 (+37)

1.4% less ownership

Funds ownership: 74.5% → 73.1% (-1.4%)

Holders
155
Holders Change
+37
Holders Change %
+31.36%
% of All Funds
3.45%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
71
Increased
45
Reduced
25
Closed
34
Calls
$8.75M
Puts
$4.62M
Net Calls
+$4.12M
Net Calls Change
+$4.54M

Top Buyers

Rank Fund Capital Flow
1
MF
Magnetar Financial
Illinois
+$58.8M
2
AA
AQR Arbitrage
Connecticut
+$41.7M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$28.2M
4
AAM
Alpine Associates Management
Florida
+$27M
5
UOC
UBS O'Connor
Illinois
+$19M

Top Sellers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
-$70.1M
2
MC
Maverick Capital
Texas
-$65.9M
3
AIM
ARK Investment Management
Florida
-$49.3M
4
OIM
Oracle Investment Management
Connecticut
-$43.3M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$28M
Name Holding Trade Value Shares
Change 		Change in
Stake
CIAS
151
Capital Investment Advisory Services
North Carolina
$1K +$634 +100 New
PA
152
Perennial Advisors
New York
$1K +$634 +100 New
GT
153
Glenmede Trust
Pennsylvania
$6 +$5.87K +927 New
MC
154
Maverick Capital
Texas
– -$65.9M -12,173,094 Closed
Point72 Asset Management
155
Point72 Asset Management
Connecticut
– -$28M -5,175,000 Closed
Capital World Investors
156
Capital World Investors
California
– -$25.3M -4,680,862 Closed
BG
157
Bellevue Group
Switzerland
– -$13.9M -2,575,000 Closed
BC
158
Broadfin Capital
New York
– -$13.5M -2,493,021 Closed
RI
159
RTW Investments
New York
– -$12.1M -2,237,607 Closed
Federated Hermes
160
Federated Hermes
Pennsylvania
– -$8.66M -1,600,000 Closed
FCMI
161
Foresite Capital Management III
California
– -$6.14M -1,135,000 Closed
PVI
162
Pura Vida Investments
New York
– -$1.64M -303,734 Closed
Victory Capital Management
163
Victory Capital Management
Texas
– -$1.62M -300,000 Closed
PP
164
PDT Partners
New York
– -$1.55M -286,310 Closed
Fuller & Thaler Asset Management
165
Fuller & Thaler Asset Management
California
– -$1.47M -271,384 Closed
FAM
166
Fred Alger Management
New York
– -$974K -180,000 Closed
EGM
167
Engineers Gate Manager
New York
– -$894K -165,321 Closed
MCM
168
Moore Capital Management
New York
– -$676K -125,000 Closed
IG
169
ING Group
Netherlands
– -$637K -117,806 Closed
IWM
170
IHT Wealth Management
Illinois
– -$365K -67,450 Closed
Wolverine Trading
171
Wolverine Trading
Illinois
– -$178K -28,152 Closed
Verition Fund Management
172
Verition Fund Management
Connecticut
– -$128K -23,697 Closed
LPL Financial
173
LPL Financial
California
– -$125K -23,095 Closed
FMT
174
First Mercantile Trust
Tennessee
– -$115K -21,320 Closed
TRCT
175
Tower Research Capital (TRC)
New York
– -$107K -19,897 Closed
4 5 6
7
8

PACB Hedge Fund Activity: Q4 2018 in Review

155 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q4 2018, worth a combined $809M — up 37% from $590M a quarter earlier.

Buyers outnumbered sellers: 71 funds opened new PACB positions and 34 closed out — a net gain of 37 holders — while 45 added to existing stakes and 25 trimmed.

The largest buyer was Magnetar Financial, opening a new position worth an estimated $58.8M. The largest seller was Consonance Capital Management, cutting an estimated $70.1M.

  • 155 institutional investors held Pacific Biosciences (PACB) as of Q4 2018, up from 118 in Q3 2018.
  • Funds reported $809M of Pacific Biosciences stock for Q4 2018, up 37% quarter-over-quarter.
  • 71 funds opened new Pacific Biosciences positions in Q4 2018 and 34 closed out, a net change of +37 holders.
  • The largest Pacific Biosciences buyer in Q4 2018 was Magnetar Financial, an estimated $58.8M added.
  • The largest Pacific Biosciences seller in Q4 2018 was Consonance Capital Management, an estimated $70.1M sold.

Based on aggregated 13F filings for Q4 2018.